# A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06954246/  
OnCo record `nct06954246` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing QLC5508 in non-small-cell lung cancer, now recruiting.

## Summary

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06954246, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Open-label Study of MHB088C for Injection Versus Treatment of Physician's Choice (TPC) in Comparing the Efficacy and Safety in Subjects With Relapsed Small Cell Lung Cancer (SCLC). Planned enrolment is 450 participants (estimated). The study started in 2025-06-04 and primary completion is expected in 2027-05. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06954246
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label Study of MHB088C for Injection Versus Treatment of Physician's Choice (TPC) in Comparing the Efficacy and Safety in Subjects With Relapsed Small Cell Lung Cancer (SCLC)
- Sponsor: Qilu Pharmaceutical
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06954246: https://clinicaltrials.gov/study/NCT06954246

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [QLC5508](https://onco.cc/drugs/qlc5508/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06954246.json